Sign up to access all valuation multiples
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
1952
1.3K+
LTM Revenue $442M
LTM EBITDA $44.0M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of November 2025, PolyPeptide reported last 12-month revenue of $442M and EBITDA of $44.0M.
In the same period, PolyPeptide generated $67.5M in LTM gross profit and -$17.6M in net income.
See PolyPeptide valuation multiples based on analyst estimatesIn the most recent fiscal year, PolyPeptide reported revenue of $422M and EBITDA of $35.4M.
PolyPeptide expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PolyPeptide valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $442M | XXX | $422M | XXX | XXX | XXX |
| Gross Profit | $67.5M | XXX | $48.9M | XXX | XXX | XXX |
| Gross Margin | 15% | XXX | 12% | XXX | XXX | XXX |
| EBITDA | $44.0M | XXX | $35.4M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| EBIT | $2.6M | XXX | -$7.5M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | -2% | XXX | XXX | XXX |
| Net Profit | -$17.6M | XXX | -$24.3M | XXX | XXX | XXX |
| Net Margin | -4% | XXX | -6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PolyPeptide has current market cap of CHF 815M (or $1.0B), and EV of CHF 837M (or $1.0B).
As of December 3, 2025, PolyPeptide's stock price is CHF 25 (or $31).
See PolyPeptide trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.0B | XXX | XXX | XXX | XXX | $-0.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialPolyPeptide's trades at 2.5x EV/Revenue multiple, and 29.5x EV/EBITDA.
See valuation multiples for PolyPeptide and 15K+ public compsAs of December 3, 2025, PolyPeptide has market cap of $1.0B and EV of $1.0B.
Equity research analysts estimate PolyPeptide's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PolyPeptide has a P/E ratio of -53.6x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 22.1x | XXX | 29.5x | XXX | XXX | XXX |
| EV/EBIT | 371.5x | XXX | -139.6x | XXX | XXX | XXX |
| EV/Gross Profit | 14.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -53.6x | XXX | -41.7x | XXX | XXX | XXX |
| EV/FCF | -19.5x | XXX | 344.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPolyPeptide's last 12 month revenue growth is 22%
PolyPeptide's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $44K for the same period.
PolyPeptide's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PolyPeptide's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PolyPeptide and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 84% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PolyPeptide acquired XXX companies to date.
Last acquisition by PolyPeptide was XXXXXXXX, XXXXX XXXXX XXXXXX . PolyPeptide acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was PolyPeptide founded? | PolyPeptide was founded in 1952. |
| Where is PolyPeptide headquartered? | PolyPeptide is headquartered in Switzerland. |
| How many employees does PolyPeptide have? | As of today, PolyPeptide has 1.3K+ employees. |
| Is PolyPeptide publicy listed? | Yes, PolyPeptide is a public company listed on SWX. |
| What is the stock symbol of PolyPeptide? | PolyPeptide trades under PPGN ticker. |
| When did PolyPeptide go public? | PolyPeptide went public in 2021. |
| Who are competitors of PolyPeptide? | Similar companies to PolyPeptide include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of PolyPeptide? | PolyPeptide's current market cap is $1.0B |
| What is the current revenue of PolyPeptide? | PolyPeptide's last 12 months revenue is $442M. |
| What is the current revenue growth of PolyPeptide? | PolyPeptide revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of PolyPeptide? | Current revenue multiple of PolyPeptide is 2.2x. |
| Is PolyPeptide profitable? | Yes, PolyPeptide is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PolyPeptide? | PolyPeptide's last 12 months EBITDA is $44.0M. |
| What is PolyPeptide's EBITDA margin? | PolyPeptide's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of PolyPeptide? | Current EBITDA multiple of PolyPeptide is 22.1x. |
| What is the current FCF of PolyPeptide? | PolyPeptide's last 12 months FCF is -$49.9M. |
| What is PolyPeptide's FCF margin? | PolyPeptide's last 12 months FCF margin is -11%. |
| What is the current EV/FCF multiple of PolyPeptide? | Current FCF multiple of PolyPeptide is -19.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
